CR7853A - Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos - Google Patents

Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos

Info

Publication number
CR7853A
CR7853A CR7853A CR7853A CR7853A CR 7853 A CR7853 A CR 7853A CR 7853 A CR7853 A CR 7853A CR 7853 A CR7853 A CR 7853A CR 7853 A CR7853 A CR 7853A
Authority
CR
Costa Rica
Prior art keywords
antibodies
same
treatment
myeloid leukemia
acute myeloid
Prior art date
Application number
CR7853A
Other languages
English (en)
Inventor
G Hoffee Mary
Tavares Daniel
J Lutz Robert
Original Assignee
Inmunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmunogen Inc filed Critical Inmunogen Inc
Publication of CR7853A publication Critical patent/CR7853A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a anticuerpos que enlazan CD33. De manera mas particular la invencion se refiere a anticuerpos anti-CD33, fragmentos y homologos de dichos anticuerpos, versiones humanizadas y recubiertas de dichos anticuerpos, equivalente funcionales y versiones mejoradas de dichos anticuerpos, inmunoconjugados y composiciones que comprenden a dichos anticuerpos y el uso de los mismos en el diagnostico, investigacion y aplicaciones terapeuticas. La invencion se refiere tambien a un polinucleotido que codifica los anticuerpos, vectores que comprendern los polinucleotidos, celulas huesped transformadas conm polinucleotidos y metodos para producir los anticuerpos.
CR7853A 2002-11-07 2005-06-01 Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos CR7853A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42433202P 2002-11-07 2002-11-07

Publications (1)

Publication Number Publication Date
CR7853A true CR7853A (es) 2005-12-16

Family

ID=32312793

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7853A CR7853A (es) 2002-11-07 2005-06-01 Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos

Country Status (24)

Country Link
US (10) US7557189B2 (es)
EP (1) EP1578446B1 (es)
JP (1) JP5354835B2 (es)
KR (1) KR20050059332A (es)
CN (2) CN1795009B (es)
AU (1) AU2003285878B2 (es)
BR (1) BR0316101A (es)
CA (1) CA2504818C (es)
CO (1) CO5580797A2 (es)
CR (1) CR7853A (es)
CY (1) CY1116406T1 (es)
DK (1) DK1578446T3 (es)
EA (1) EA010570B1 (es)
EC (1) ECSP055831A (es)
ES (1) ES2539627T3 (es)
HU (1) HUE026914T2 (es)
IL (2) IL168295A (es)
MX (1) MXPA05004712A (es)
NO (1) NO338498B1 (es)
NZ (1) NZ539395A (es)
PT (1) PT1578446E (es)
SI (1) SI1578446T1 (es)
WO (1) WO2004043344A2 (es)
ZA (1) ZA200503075B (es)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
WO2006040322A1 (en) * 2004-10-12 2006-04-20 Crucell Holland B.V. Binding molecules for treatment and detection of cancer
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
JP5165387B2 (ja) 2005-02-11 2013-03-21 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EA020324B1 (ru) 2006-07-18 2014-10-30 Санофи-Авентис АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
HUE039385T2 (hu) 2007-04-12 2018-12-28 Brigham & Womens Hospital Inc ABCB5 rákterápiás célzása
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
EP2281006B1 (en) 2008-04-30 2017-08-02 Immunogen, Inc. Cross-linkers and their uses
EP3009454A3 (en) 2009-04-20 2016-10-19 Oxford Bio Therapeutics Limited Antibodies specific to cadherin-17
EP2437790B1 (en) 2009-06-03 2019-02-20 Immunogen, Inc. Conjugation methods
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
UY32913A (es) 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
JP2013506709A (ja) 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
US8524240B2 (en) 2009-10-26 2013-09-03 Djordje Atanackovic Diagnosis and therapy of hematological malignancies
IN2012DN03824A (es) * 2009-10-30 2015-08-28 Merck Sharp & Dohme
WO2011063346A1 (en) * 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
JP5911813B2 (ja) * 2010-03-04 2016-04-27 ベット・セラピューティクス・インコーポレイテッドＶｅｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Ｃｄ２０に対するモノクローナル抗体
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
NZ610091A (en) * 2010-10-20 2015-02-27 Oxford Biotherapeutics Ltd Antibodies
WO2012074097A1 (ja) * 2010-12-03 2012-06-07 協和発酵キリン株式会社 抗ｃｄ３３抗体
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
KR20140010076A (ko) 2011-02-15 2014-01-23 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
TR201902180T4 (tr) 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
MX350954B (es) 2011-06-21 2017-09-26 Immunogen Inc Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos.
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
CN102768283B (zh) * 2012-07-23 2015-03-04 北京大学人民医院 一种检测或辅助检测髓系白血病细胞分化阶段的试剂盒
HK1211208A1 (zh) 2012-08-22 2016-05-20 Immunogen, Inc. 細胞毒性苯並二氮呯衍生物
KR20150046316A (ko) 2012-08-31 2015-04-29 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP2961435B1 (en) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
AU2014285079A1 (en) 2013-07-05 2016-01-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble CD33 for treating myelodysplastic syndromes (MDS)
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
CA2931340A1 (en) 2013-12-13 2015-06-18 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
CA2928952A1 (en) * 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
KR20240042192A (ko) * 2013-12-17 2024-04-01 크링 바이오테라퓨틱스 비.브이. 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법
CN106795221B (zh) * 2014-04-03 2022-06-07 塞勒克提斯公司 用于癌症免疫治疗的cd33特异性嵌合抗原受体
SI3128997T1 (sl) 2014-04-08 2020-11-30 Boston Pharmaceuticals Inc. Vezavne molekule specifične za IL-21 in njihove uporabe
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
KR20170004003A (ko) * 2014-05-20 2017-01-10 이뮤노젠 아이엔씨 급성 골수성 백혈병의 특성화 및 치료 방법
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
AU2015311951B2 (en) 2014-09-02 2021-04-08 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
PT3189056T (pt) 2014-09-03 2020-09-04 Immunogen Inc Derivados citotóxicos de benzodiazepina
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
DK3590962T3 (da) * 2014-10-23 2021-12-13 Singh Molecular Medicine Llc Enkeltdomæneantistoffer rettet mod intracellulære antigener
KR102781223B1 (ko) 2014-11-10 2025-03-12 메디뮨 리미티드 Cd73에 특이적인 결합 분자 및 이의 용도
US20160129108A1 (en) 2014-11-11 2016-05-12 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
EA202092609A1 (ru) * 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2016120218A1 (en) 2015-01-26 2016-08-04 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
EP4190814A1 (en) 2015-05-29 2023-06-07 Amphivena Therapeutics, Inc. Methods of using bispecific cd33 and cd3 binding proteins
KR20180033502A (ko) 2015-06-12 2018-04-03 알렉터 엘엘씨 항-cd33 항체 및 그의 사용 방법
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
SMT202100092T1 (it) 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
MD3313845T2 (ro) 2015-06-29 2021-02-28 Immunogen Inc Conjugați cu anticorpi având cisteină modificată prin inginerie genetică
US12509530B2 (en) 2015-08-27 2025-12-30 Singh Moelcular Medicine, LLC Single domain antibodies directed against intracellular antigens
LT3374398T (lt) 2015-11-10 2020-09-10 Medimmune, Llc Asct2 atžvilgiu specifinės surišančios molekulės ir jų panaudojimai
EP3903818A1 (en) 2015-11-19 2021-11-03 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US20170189548A1 (en) 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
JP2019510741A (ja) 2016-02-05 2019-04-18 イミュノジェン・インコーポレーテッド 細胞結合剤・細胞毒性剤コンジュゲートを調製するための効率的なプロセス
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
PE20190622A1 (es) 2016-06-02 2019-04-26 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (en) 2016-06-09 2020-05-06 Seattle Genetics, Inc. COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS
EP4413996A3 (en) * 2016-09-20 2024-10-23 Aronora, Inc. Novel antibodies against factor xi and uses thereof
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
RU2019114863A (ru) * 2016-11-02 2020-12-03 Иммуноджен, Инк. Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
CN110662770A (zh) 2016-11-23 2020-01-07 比奥维拉迪维治疗股份有限公司 结合凝血因子ix和凝血因子x的双特异性抗体
TWI755450B (zh) 2016-11-23 2022-02-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN116785450A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
JP2020519640A (ja) * 2017-05-17 2020-07-02 イミュノジェン， インコーポレイテッド 抗ｃｄ３３イムノコンジュゲート投与計画
MA47691A (fr) 2017-08-03 2020-01-08 Alector Llc Anticorps anti-cd33 et leurs procédés d'utilisation
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
CA3075896A1 (en) 2017-09-22 2019-03-28 Immunogen, Inc. Methods of preventing methionine oxidation in immunoconjugates
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US20190160089A1 (en) 2017-10-31 2019-05-30 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
EP3752195A4 (en) 2018-02-14 2021-11-17 Viela Bio, Inc. FELINE MCDONOUGH'S SARCOMA (FMS) -LIKE TYROSINKINASE-3 RECEPTOR LIGANDS (FLT3L) ANTIBODIES AND USES THEREOF IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
SG11202007055QA (en) * 2018-03-08 2020-09-29 Phanes Therapeutics Inc Anti-claudin 18.2 antibodies and uses thereof
CA3093838A1 (en) 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
EP3784776A4 (en) * 2018-05-23 2022-01-26 National University of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
AU2019284911B2 (en) 2018-06-13 2026-04-09 Novartis Ag BCMA chimeric antigen receptors and uses thereof
KR20210063351A (ko) * 2018-08-28 2021-06-01 암브룩스, 인코포레이티드 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도
BR112021003016A2 (pt) 2018-08-31 2021-05-18 Alector Llc anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um anticorpo e para prevenir, reduzir o risco ou tratar uma doença e composição farmacêutica
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
US12398402B2 (en) 2018-09-12 2025-08-26 Fred Hutchinson Cancer Center Reducing CD33 expression to selectively protect therapeutic cells
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US12103969B2 (en) * 2018-09-25 2024-10-01 Academia Sinica Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
US20210324076A1 (en) * 2018-10-12 2021-10-21 Amphivena Therapeutics Inc Cd33×cd3 binding proteins for treating inflammatory conditions and diseases
US20220226375A1 (en) * 2018-11-07 2022-07-21 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
US20220332800A1 (en) 2018-11-20 2022-10-20 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
WO2020123947A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
AU2020240310A1 (en) 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
EP3947395A1 (en) 2019-03-29 2022-02-09 ImmunoGen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
HUE065484T2 (hu) 2019-04-26 2024-05-28 Immunogen Inc Camptothecin-származékok
WO2020223445A1 (en) 2019-04-30 2020-11-05 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
CA3138058A1 (en) 2019-05-20 2020-11-26 Matthew T. Burger Mcl-1 inhibitor antibody-drug conjugates and methods of use
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
JP7788859B2 (ja) * 2019-06-26 2025-12-19 メモリアル スローン ケタリング キャンサー センター がんを処置するための抗ｃｄ３３抗体
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN116670268A (zh) 2019-11-22 2023-08-29 免疫医疗有限公司 包含e2泛素或泛素样缀合结构域和用于特异性蛋白质降解的靶向结构域的融合蛋白
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN116194476A (zh) * 2020-04-14 2023-05-30 维尔生物科技有限公司 针对sars-cov-2的抗体和其使用方法
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
CA3193594A1 (en) 2020-09-11 2022-03-17 Medimmune Limited Therapeutic b7-h4 binding molecules
EP4211663B1 (en) 2020-09-12 2026-02-18 MedImmune Limited A scoring method for an anti-b7h4 antibody-drug conjugate therapy
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
AU2021386367A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
CN117062611A (zh) 2021-01-26 2023-11-14 惠和生物技术(上海)有限公司 嵌合抗原受体（car）构建体和表达car构建体的nk细胞
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CA3212630A1 (en) 2021-03-18 2022-09-22 Medimmune Limited Therapeutic binding molecules
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
EP4634224A1 (en) 2022-12-14 2025-10-22 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
EP4667497A1 (en) 2023-02-13 2025-12-24 Shaoxing Institute, Zhejiang University Bispecific antibody and use thereof
EP4720130A1 (en) * 2023-06-01 2026-04-08 Research Institute at Nationwide Children's Hospital Cd-33 protein-binding compositions and methods related thereto
WO2025027472A2 (en) 2023-07-31 2025-02-06 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
JPH05503632A (ja) 1989-12-14 1993-06-17 スローン　―　ケターリング・インスティチュート・フォー・キャンサー・リサーチ モノクローナル抗体ｍ１９５の超可変領域の治療的使用およびその構築
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
DE60140063D1 (de) * 2000-08-08 2009-11-12 Immunomedics Inc Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper
CN1489474A (zh) * 2001-01-26 2004-04-14 Ӣϣ��̩��˹��˾ 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法
HUE026914T2 (en) * 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
WO2006113623A2 (en) * 2005-04-15 2006-10-26 Immunogen, Inc. Elimination of heterogeneous or mixed cell population in tumors
JP2011524421A (ja) * 2008-06-16 2011-09-01 イミュノジェン・インコーポレーテッド 新規の相乗効果
KR20170004003A (ko) * 2014-05-20 2017-01-10 이뮤노젠 아이엔씨 급성 골수성 백혈병의 특성화 및 치료 방법

Also Published As

Publication number Publication date
CA2504818A1 (en) 2004-05-27
NZ539395A (en) 2009-01-31
AU2003285878A1 (en) 2004-06-03
US9359442B2 (en) 2016-06-07
EP1578446B1 (en) 2015-04-08
US8337855B2 (en) 2012-12-25
US20080167458A1 (en) 2008-07-10
US10000566B2 (en) 2018-06-19
SI1578446T1 (sl) 2015-07-31
US20090291090A1 (en) 2009-11-26
PT1578446E (pt) 2015-07-22
EA010570B1 (ru) 2008-10-30
EP1578446A4 (en) 2008-07-30
US20050118183A1 (en) 2005-06-02
US7342110B2 (en) 2008-03-11
US8119787B2 (en) 2012-02-21
ZA200503075B (en) 2006-09-27
HUE026914T2 (en) 2016-08-29
WO2004043344A2 (en) 2004-05-27
CO5580797A2 (es) 2005-11-30
US7557189B2 (en) 2009-07-07
IL168295A (en) 2011-02-28
EA200500778A1 (ru) 2006-02-24
US20110206700A1 (en) 2011-08-25
JP5354835B2 (ja) 2013-11-27
DK1578446T3 (en) 2015-06-29
NO20052693L (no) 2005-06-06
CN1795009B (zh) 2014-07-09
IL211385A0 (en) 2011-04-28
MXPA05004712A (es) 2005-11-23
ECSP055831A (es) 2005-08-11
US20110008840A1 (en) 2011-01-13
CN1795009A (zh) 2006-06-28
CN102875680A (zh) 2013-01-16
US20180362646A1 (en) 2018-12-20
AU2003285878B2 (en) 2011-04-28
CN102875680B (zh) 2015-04-22
NO20052693D0 (no) 2005-06-06
CA2504818C (en) 2013-04-23
ES2539627T3 (es) 2015-07-02
US20140248267A1 (en) 2014-09-04
US20160362490A1 (en) 2016-12-15
CY1116406T1 (el) 2017-02-08
NO338498B1 (no) 2016-08-22
US8747851B2 (en) 2014-06-10
WO2004043344A3 (en) 2004-12-09
BR0316101A (pt) 2005-09-27
EP1578446A2 (en) 2005-09-28
HK1091132A1 (en) 2007-01-12
KR20050059332A (ko) 2005-06-17
US20130078241A1 (en) 2013-03-28
JP2006505277A (ja) 2006-02-16
US20060177455A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
ECSP055831A (es) Anticuerpos anti-cd33 y método para tratamiento de leucemia mieloide aguda utilizando los mismos
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
PE20242042A1 (es) Anticuerpos especificos para flt3 y sus usos
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
BRPI0410031A (pt) variantes fc otimizadas e métodos para sua geração
NO20080362L (no) CD19-antistoffer og deres anvendelser
BRPI0412667A (pt) sìntese regiosseletiva de cci - 779
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
AR065686A1 (es) Mutaciones de k- ras y b- raf y terapia con anticuerpos anti- egfr
AR046933A1 (es) Eficacia de humectacion mejorada mediante el uso de hidroxialquilurea
ATE541571T1 (de) Diarylhydantoin-verbindung
PA8556201A1 (es) Alquinos como inhibidores de metaloproteinasa de matriz
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
MXPA03008738A (es) Combinaciones inmunoterapeuticas para el tratamiento de tumores que sobre-expresan glangliosidos.
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
BRPI0509154A (pt) composição quìmica e usos
DE112004000860D2 (de) Gating-Verfahren, Gating-Gerät, sowie Therapieeinrichtung
ITBZ20040048A1 (it) Metodo per l'identificazione della trasformazione neoplastica, con particolare riferimento al cancro prostatico
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
DE60137607D1 (de) Substituierte cyclohexene

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)